PD biomarker data is frequently used to determine the efficacy and safety of investigational and therapeutic agents in a specific patient subset during clinical trials. PK and PD analysis are complementary techniques, and testing can be performed on one plasma sample per patient.
Our team will partner with you to develop specialized biomarker studies that support the individual needs of your discovery or clinical trial program.
Using liquid chromatography with tandem mass spectrometry (LC-MS/MS), our analytical scientists have developed highly sensitive assays for measuring the up/down-regulation of endogenous biomarkers in plasma and other biological matrices. For detecting endogenous biomarkers at low levels in biological fluids, LC-MS/MS provides superior selectivity and accuracy.
We implemented standard operating procedures and validated methods that align with international regulatory guidelines, and our laboratory has developed PD biomarker assays to perform safety and efficacy testing of multiple compound classes.